Donafenib, sintilimab, and HAIC before liver cancer surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (donafenib and sintilimab) plus a liver-directed chemotherapy infusion (HAIC) before surgery for liver cancer that can be removed. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of liver cancer called hepatocellular carcinoma (HCC) that can be removed with surgery.
- You are between 18 and 80 years old.
- Your cancer is at a certain stage (CNLC stage IIb to IIIa) and the surgeon expects to leave enough healthy liver after surgery.
- You have not had any prior treatment for liver cancer (like chemotherapy, targeted therapy, or procedures like TACE or HAIC).
- You do not have serious heart problems, uncontrolled autoimmune diseases, or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three treatments for advanced liver cancer that can't be removed by surgery. It uses an immunotherapy drug (cadonilimab), a targeted therapy pill (lenvatinib), and a direct chemotherapy infusion into the liver (HAIC). The goal is to see if this combo can shrink tumors and improve outcomes.
This trial tests giving a liver-directed chemotherapy (HAIC) plus an immunotherapy (PD-1) before surgery, followed by more immunotherapy after surgery, for people with a specific type of liver cancer that has a high chance of coming back. The goal is to see if this approach can reduce the risk of recurrence.
This trial tests a combination of three treatments for advanced liver cancer that cannot be removed by surgery: a targeted oral drug (Donafenib), an immunotherapy (Sintilimab), and a type of chemotherapy given directly into the liver artery. The goal is to see if this triple therapy works better than current options for people who have not had any prior cancer treatment.
This trial tests a combination of three treatments for advanced liver cancer (BCLC stage C): HAIC (chemotherapy directly into the liver), adebrelimab (immunotherapy that helps your immune system fight cancer), and apatinib (a targeted drug that cuts off blood supply to tumors). It may be an option if you have not had any prior systemic (whole-body) therapy for liver cancer.
This trial studies HAIC, a type of targeted treatment delivered into the liver, for advanced hepatocellular carcinoma (liver cancer) that has already been treated with immune and anti-blood-vessel therapies. It aims to see whether HAIC can help control the cancer safely after those earlier treatments.
This trial tests a combination of treatments—chemotherapy delivered through the liver artery (HAIC), a targeted drug (donafenib), and an immunotherapy (sintilimab)—given before and after surgery for liver cancer that has a high chance of coming back. The goal is to see if this approach can lower the risk of recurrence.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.